Trial Profile

NOPHO-DBH AML 2012 Protocol Research study for treatment of children and adolescents with acute myeloid leukaemia 0-18 years NOPHO-DBH AML protocol. Research study for treatment of children and adolescents with acute myeloid leukaemia 0-18 years

Status: Recruiting

Phase of Trial: Phase III

Latest Information Update: 13 Sep 2023

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Daunorubicin liposomal (Primary) ; Cytarabine; Etoposide; Fludarabine; Mitoxantrone
Indications Acute myeloid leukaemia
Focus Therapeutic Use
Acronyms AML 2012; NOPHO-DBH AML 2012
Sponsors Ixaka

28 Apr 2022 Planned number of patients changed from 325 to 850.
15 Apr 2013 New source identified and integrated: ClinicalTrials.gov record.
23 Feb 2013 Additional lead trial centres identified as reported by European Clinical Trials Database.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com